BSE Live
Mar 16, 16:01Prev. Close
1560.80
Open Price
1579.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 16, 16:03Prev. Close
1561.30
Open Price
1565.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Ipca Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 25.00 | 12.50 | |
| Total Share Capital | 25.00 | 12.50 | |
| Reserves and Surplus | 312.59 | 263.17 | |
| Total Reserves and Surplus | 312.59 | 263.17 | |
| Total Shareholders Funds | 337.59 | 275.67 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 10.52 | 47.62 | |
| Deferred Tax Liabilities [Net] | 43.73 | 29.28 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 54.25 | 76.90 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 209.85 | 107.02 | |
| Trade Payables | 59.07 | 57.78 | |
| Other Current Liabilities | 26.32 | 21.05 | |
| Short Term Provisions | 11.46 | 21.48 | |
| Total Current Liabilities | 306.71 | 207.32 | |
| Total Capital And Liabilities | 698.55 | 559.90 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 291.46 | 180.38 | |
| Intangible Assets | 2.84 | 1.70 | |
| Capital Work-In-Progress | 28.17 | 13.83 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 322.46 | 195.92 | |
| Non-Current Investments | 10.29 | 15.15 | |
| Deferred Tax Assets [Net] | 0.79 | 0.28 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | |
| Total Non-Current Assets | 333.54 | 211.34 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 173.87 | 150.22 | |
| Trade Receivables | 157.16 | 139.04 | |
| Cash And Cash Equivalents | 4.17 | 4.75 | |
| Short Term Loans And Advances | 29.82 | 54.54 | |
| OtherCurrentAssets | 0.00 | 0.00 | |
| Total Current Assets | 365.01 | 348.55 | |
| Total Assets | 698.55 | 559.90 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 66.64 | 62.20 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 73.76 | 78.40 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 12.76 | 6.59 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 34.64 | 24.31 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 390.97 | 340.16 | |
| Other Earnings | -- | 2.23 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 20.90 | 8.40 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | -- | |
| Non-Current Investments Unquoted Book Value | 10.29 | 20.40 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
18.02.2026
Buy Ipca Laboratories; target of Rs 1710: Prabhudas Lilladher
17.02.2026
09.02.2026
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher
16.03.2026
15.03.2026
13.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth